R1 RCM

R1 RCM was founded as Accretive Health in 2003 by Mary Tolan and Michael Cline. Tolan served as the company's president, chief executive officer, and board director until 2013. Cline served as board chairman between 2009 and 2013.In 2012, responding to a Senate inquiry, the company stated that nine thefts of patient data-bearing company laptops had occurred in 2011, and that 30 company laptops had lacked encryption. As a consequence, in 2013, Accretive Health entered into a 20-year settlement with the Federal Trade Commission over its data security measures.In July 2012, Accretive Health entered into a $2.5 million settlement with the Minnesota Attorney General following an investigation into the company's debt collection practices. The company admitted no wrongdoing. Accretive Health was barred from operating in Minnesota for two to six years under a settlement agreement announced July 30th, 2012 by Minnesota Attorney General Lori Swanson.In April 2013, Mary Tolan stepped down as CEO. Tolan was replaced by former Dell executive Stephen Schuckenbrock.In March 2014, as a result of missed financial restatements, Accretive Health was delisted from the New York Stock Exchange. Over-the-counter trading continued.

On July 21, 2014, Emad Rizk replaced Schuckenbrock as CEO.In December 2014, the company restated certain previously filed financial statements and, in June 2015, announced that they had completed their 2014 SEC filings The company filed its 2015 Q2 10-Q with the SEC in August 2015.In 2015, Ascension selected Accretive Health as its exclusive hospital revenue cycle partner. As part of the transaction, Ascension and TowerBrook Capital Partners invested $200M to support growth initiatives at Accretive Health.In 2017, Accretive Health was renamed as R1 RCM.In mid-2017, R1 RCM announced a further expansion of the agreement with Ascension to include an additional $1.5B in net patient revenue handled, which included physician group revenue cycle services.In August 2020 R1 RCM was hit with a ransomware attack.